Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — MST Access Biotech & Healthcare Webinar October 2026
14 slides from Bcal Diagnostics's conference presentation, October 2026
Slide 1: Transforming early cancer detection with novel blood tests
Transforming early cancer detection with novel blood tests INVESTOR PRESENTATION ASX:BDX Anne-Louise Arnett Chief Executive Officer MST Access Biotech & Healthcare Webinar October 2026
Slide 2: BCAL is building an Australian platform for earlier cancer detection
BCAL TODAY BCAL is building an Australian platform for earlier cancer detection BCAL is an Australian healthcare company developing and commercialising blood- based technology designed to support earlier cancer detection. ABOUT BCAL THE PLATFORM TODAY Australian healthcare company engaged in early c
Slide 3: Three forces driving demand for early detection
MARKET DYNAMICS Three forces driving demand for early detection 48% of Australian women aged 50–74 do not participate in routine breast screening.* 1 2 3 Today's tools work too late Diagnostics is going less invasive Consumers are taking charge Most cancers are still found once symptoms The shift is
Slide 4: One channel, an expanding portfolio
COMMERCIAL PLATOFRM One channel, an expanding portfolio TEST INDICATION STATUS PRICE BREASTESTplus Breast cancer rule-out Available now $300 Avantect® Pancreatic High-risk patients Available now $1,495 Avantect® Ovarian High-risk patients Available now $1,495 Elevated lifestyle risk, Avantect® Multi
Slide 5: A national channel, already built
COMMERCIAL PLATOFRM A national channel, already built The infrastructure is the asset 1 Pathology networks 2 Ordering where doctors already work National collection and testing through Sonic Healthcare Referral forms embedded in Best Practice and Medical and Healius. BREASTESTplus available at 96 So
Slide 6: The channel is already generating commercial activity
COMMERCIAL PLATOFRM The channel is already generating commercial activity Early traction across access, testing and demand BREASTESTplus Avantect® Pancreatic & Ovarian EarlyDetection.com.au 93 $136k 53,017 pathology collection sites revenue since January~ June 2026 website visits since January ~June
Slide 7: Large and growing markets
MARKET OPPORTUNITY Large and growing markets Global cancer diagnostics, by indication US$20.1B1 US$4.93B2 US$1.54B3 Breast cancer diagnostics Pancreatic cancer diagnostics Ovarian cancer diagnostics 8% CAGR, reaching US$40.7B by 2034 7.2% CAGR 6.6% CAGR 2.86M Australian women a year are addressable
Slide 8: The Australian addressable market
MARKET OPPORTUNITY The Australian addressable market Indicative market sizing demonstrates the scale of opportunity across BCAL's portfolio MARKET SIZE BY TEST LINE (AUSTRALIA) Opportunity Price Opportunity Test line Opportunity ($) (AUD) (population) BREASTESTplus – women 50+ $300 1.02M $306M $1.8B
Slide 9: An active global early detection landscape
MARKET OPPORTUNITY An active global early detection landscape A growing international pipeline creates potential licensing and commercialisation opportunities for BCAL in Australia • Rapidly developing global market for blood-based GLOBAL INNOVATION IS EXPANDING THE OPPORTUNITY early cancer detectio
Slide 10: Multiple pathways to extend the platform
GROWTH STRATEGY Multiple pathways to extend the platform Partnerships, investment and licensing create additional routes to growth Sonic Healthcare USA ClearNote Health Genetic Signatures Strategic optionality US expansion pathway Licensing and portfolio Strategic investment / Future licensing/ expa
Slide 11: Catalysts
GROWTH Catalysts STRATEGY Recent and upcoming milestones SEPT 2026 Avantect® Multi-cancer introduced Fourth product live on the national channel, with cancer-signal-of-origin capability. NOV 2026 BREASTESTplus 2 launch Broader eligibility across women 30+ and all breast densities, at a $300 screenin
Slide 12: A national early detection platform with multiple pathways to growth
INVESTMENT CASE A national early detection platform with multiple pathways to growth National commercial infrastructure An expanding multi-product portfolio Sonic, Healius, GP referral systems and telehealth From one proprietary test to four tests available provide national access, with each new tes
Slide 13: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by BCAL The forward-looking statements are based on information available to Not An Offer Diagnostics Ltd ABN 51 142 051 223 (BCAL or the Company). BCAL as at the date of this Presentation. Circumstances may change This Presentation is no
Slide 14: Thank you.
Thank you. For further Information Anne-Louise Arnett Chief Executive Officer Aarnett@bcaldiagnostics.com Information portal about early cancer detection. earlydetection.com.au Access telehealth appointments with medical professionals.
BCAL Diagnostics — MST Access Biotech & Healthcare Webinar October 2026 on 6ix